Selective Inhibition of Tyrosine Kinase 2 With Deucravacitinib (BMS-986165) Compared With Janus Kinase 1−3 Inhibitors

Anjaneya Chimalakonda; James Burke; Lihong Cheng; Ian Catlett; Aditya Patel; Jun Shen; Ihab Girgis; Subhashis Banerjee; John Throup

doi:10.25251/skin.4.supp.108

Anjaneya Chimalakonda
James Burke

Employee at the time the analysis was conducted.

Lihong Cheng
Ian Catlett
Aditya Patel
Jun Shen
Ihab Girgis
Subhashis Banerjee
John Throup

Keywords

Pharmacology, Tyrosine Kinase 2 Inhibitor, Deucravacitinib, Janus Kinase Inhibitor, JAK, TYK2

Abstract

Abstract not available.

References

1. Burke JR et al. Sci Transl Med. 2019;11:1-16.

2. Papp K et al. N Engl J Med. 2018;379:1313-1321.

3. Girgis IG et al. Presented at: Triennial Meeting of the Skin Inflammation and Psoriasis International Network; April 25-27, 2019; Paris, France.

4. Klünder B et al. Clin Pharmacokinet. 2019;58:1045-1058.

5. Xie R et al. Int J Clin Pharmacol Ther. 2019;57:464-473.

6. Zhang X et al. CPT Pharmacometrics Syst Pharmacol. 2017;6:804-813.

7. Dowty ME et al. Pharmacol Res Perspect. 2019;7:e00537.

8. McInnes IB et al. Arthritis Res Ther. 2019;21:183.

9. Xeljanz [package insert]. New York, NY: Pfizer Inc.; 2019.

10. Winthrop KL. Nat Rev Rheumatol. 2017;13:234-243.

11. Gadina M et al. Rheumatology (Oxford). 2019;58:i4-i16.

Poster PDF

Published

Oct 27, 2020

DOI https://doi.org/10.25251/skin.4.supp.108

How to Cite

Chimalakonda, A., Burke, J., Cheng, L., Catlett, I., Patel, A., Shen, J., Girgis, I., Banerjee, S., & Throup, J. (2020). Selective Inhibition of Tyrosine Kinase 2 With Deucravacitinib (BMS-986165) Compared With Janus Kinase 1−3 Inhibitors. SKIN The Journal of Cutaneous Medicine, 4(6), s108. https://doi.org/10.25251/skin.4.supp.108

Issue

Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)

Section

Dermatopharmacology

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Richard Warren , April Armstrong , Melinda Gooderham, Bruce Strober , Diamant Thaci, Shinichi Imafuku, Howard Sofen, Lynda Spelman, Neil Korman, Min Zheng, Elizabeth Colston, John Throup , Sundeep Kundu, Renata Kisa, Subhashis Banerjee, Andrew Blauvelt, Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Diamant Thaci, Kenneth Gordon , Melinda Gooderham, Bruce Strober , Neil Korman, Subhashis Banerjee, Subhashis Banerjee, Elizabeth Colston, Jonghyeon Kim, John Throup, Akimichi Morita, Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Psoriasis: Integrated Laboratory Parameter Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
April Armstrong , Bruce Strober , Kenneth Gordon , Joe Zhuo, Brandon Becker, Renata Kisa, John Throup, Jonghyeon Kim, Kim Papp, Deucravacitinib Improves Psoriasis Symptoms and Signs Diary Domain Scores in Patients With Moderate to Severe Plaque Psoriasis: Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Studies , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Mark Lebwohl, Alexander Egeberg, Misti Linaberry, Kim Hoyt, Subhashis Banerjee, Renata M. Kisa, Bruce Strober, Deucravacitinib in moderate to severe plaque psoriasis: liver transaminase results from the phase 3 POETYK PSO program , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Andrew Blauvelt, Phoebe Rich, Howard Sofen, Jo Lambert, Joe Merola, Mark Lebwohl, Lauren Hippeli, Renata Kisa, Subhashis Banerjee, Alexa Kimball, Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo in scalp, nail, and palmoplantar psoriasis: subset analyses of the phase 3 POETYK PSO-1 and PSO-2 trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 4 (2022): July 2022 Issue
Andrew Blauvelt, Phoebe Rich, Howard Sofen, Jo Lambert, Joseph F Merola, Mark Lebwohl, Thomas Scharnitz, Kim Hoyt, Renata M Kisa, Subhashis Banerjee, Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in scalp, nail, and palmoplantar psoriasis: subgroup analyses of the phase 3 POETYK PSO-1 and PSO-2 trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
April W. Armstrong, Mark Lebwohl, Richard B. Warren, Howard Sofen, Shinichi Imafuku, Mamitaro Ohtsuki, Lynda Spelman, Thierry Passeron, Kim A. Papp, Renata M. Kisa, Victoria Berger, Eleni Vritzali, Kim Hoyt, Matthew J. Colombo, Subhashis Banerjee, Bruce Strober, Diamant Thaçi, Andrew Blauvelt, Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 6 (2023): November 2023 Issue
Richard Warren, Howard Sofen, Shinichi Imafuku, Jacek Szepietowski, Andrew Blauvelt, Lynda Spelman, Jessica Toms, Alex Buck, Subhashis Banerjee, Alan Menter, Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Alan Menter, Andrew Blauvelt, Bruce Strober, Matthew Colombo, Renata Kisa, Sudeep Kundu, Subhashis Banerjee, Craig Leonardi, Deucravacitinib (BMS-986165), an Oral, Allosteric Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement and Improves Quality of Life in Patients With Psoriasis , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Mark Lebwohl, Richard B. Warren, Howard Sofen, Shinichi Imafuku, Carle Paul, Jacek C. Szepietowski, Lynda Spelman, Thierry Passeron, Elizabeth Colston, Lauren Hippeli, Andrew Napoli, Renata M. Kisa, Subhashis Banerjee, Alan Menter, Diamant Thaçi, Andrew Blauvelt, Deucravacitinib long-term efficacy with continuous treatment in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®

1 2 3 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Similar Articles

Most read articles by the same author(s)